ELAN vs. RGEN: Elanco Animal Health vs. Repligen Stock Comparison
How do Elanco Animal Health (ELAN) and Repligen (RGEN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Elanco Animal Health (ELAN) and Repligen (RGEN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ELAN is classified in Pharmaceuticals while RGEN is classified in Life Sciences Tools & Services.
| Profile Item | ELAN | RGEN |
|---|---|---|
| Name | Elanco Animal Health Incorporated | Repligen Corporation |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Pharmaceuticals | Life Sciences Tools & Services |
| GICS Sub-Industry | Pharmaceuticals | Life Sciences Tools & Services |
| Market Capitalization | 12.86 billion USD | 11.09 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | September 20, 2018 | April 29, 1986 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ELAN | RGEN |
|---|---|---|
| Total Return (1Y) | 24.03% | 23.28% |
| Total Return (3Y, Annualized) | 37.47% | 6.20% |
| Total Return (5Y, Annualized) | -4.24% | -8.41% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ELAN | RGEN |
|---|---|---|
| Volatility (1Y, Annualized) | 43.57% | 46.73% |
| Beta (5Y) | 1.65 | 1.11 |
| Max Drawdown (5Y) | -75.59% | -64.67% |
| Avg. Volume (3M) | 5.65M | 1.18M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ELAN | RGEN |
|---|---|---|
| Sharpe Ratio (1Y) | 0.45 | 0.41 |
| Sortino Ratio (1Y) | 0.66 | 0.60 |
Profitability
ROE (TTM)
Elanco Animal Health (ELAN) has no ROE value reported for this period; Repligen (RGEN) reports a negative figure of -0.57%, which needs context because negative ROE can reflect losses or negative shareholders’ equity.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- ELAN
- --
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.57%
- Max
- 109.18%
- Q3
- 6.23%
- RGEN
- -0.57%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both Elanco Animal Health (ELAN) at -2.86% and Repligen (RGEN) at -1.47% report negative net margin values, usually indicating net losses over the period.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-2.86%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- ELAN
- -2.86%
- Q1
- -4.14%
- Min
- -17.05%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-1.47%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- RGEN
- -1.47%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Elanco Animal Health (ELAN) at 6.64% and Repligen (RGEN) at 6.19% run core operations about as efficiently as their industries’ norm — neither stands out on operating profitability.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.64%
- Max
- 83.12%
- Q3
- 14.77%
- ELAN
- 6.64%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.19%
- Max
- 83.12%
- Q3
- 14.77%
- RGEN
- 6.19%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ELAN | RGEN |
|---|---|---|
| ROE (TTM) | -- | -0.57% |
| ROA (TTM) | -- | 1.40% |
| Net Margin (TTM) | -2.86% | -1.47% |
| Operating Margin (TTM) | 6.64% | 6.19% |
| Gross Margin (TTM) | 56.18% | 53.77% |
Growth
Revenue Growth
Both Elanco Animal Health (ELAN) at 6.22% and Repligen (RGEN) at 16.36% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Only one side can be read here: Elanco Animal Health (ELAN) reports EPS growth of -169.12%, ranked against its industry; Repligen (RGEN) has no EPS growth figure this period.
Growth Metrics
| Metric | ELAN | RGEN |
|---|---|---|
| Revenue Growth (YoY) | 6.22% | 16.36% |
| Revenue Growth (3Y CAGR) | 2.25% | -2.70% |
| EPS Growth (YoY) | -169.12% | -- |
| EPS Growth (3Y CAGR) | -- | -35.73% |
Financial Strength
Current Ratio (MRQ)
Short-term liquidity can only be read on one side of this pairing: Repligen (RGEN) shows current ratio of 9.88 against its industry benchmark, while Elanco Animal Health (ELAN) has no reading this period.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
- ELAN
- --
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.88
- Max
- 25.13
- Q3
- 12.13
- RGEN
- 9.88
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both Elanco Animal Health (ELAN) at 0.64 and Repligen (RGEN) at 0.33 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.64
- Max
- 1.42
- Q3
- 0.65
- ELAN
- 0.64
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.33
- Max
- 1.42
- Q3
- 0.65
- RGEN
- 0.33
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ELAN | RGEN |
|---|---|---|
| Current Ratio (MRQ) | -- | 9.88 |
| Debt / Equity (MRQ) | 0.64 | 0.33 |
| Net Debt / EBITDA | 3.49 | -1.19 |
Dividends
Dividend Yield (TTM)
Neither Elanco Animal Health (ELAN) nor Repligen (RGEN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ELAN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- RGEN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Elanco Animal Health (ELAN) nor Repligen (RGEN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ELAN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- RGEN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ELAN | RGEN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Neither Elanco Animal Health (ELAN) nor Repligen (RGEN) reports a P/E ratio value for this period, so a direct comparison isn’t possible.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- ELAN
- --
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- RGEN
- --
P/S Ratio (TTM)
Elanco Animal Health (ELAN) at 2.50 sits in the cheaper P/S ratio quartile while Repligen (RGEN) at 13.77 prices around its industry’s middle — ELAN costs less per dollar of sales, though read it alongside growth and margins.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.50
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- ELAN
- 2.50
- Min
- 0.01
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.77
- Max
- 58.18
- Q3
- 25.77
- RGEN
- 13.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Elanco Animal Health (ELAN) at 1.95 and Repligen (RGEN) at 4.70 are valued close to their industries’ norm against book — neither stands out from peers.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.95
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- ELAN
- 1.95
- Q1
- 1.69
- Min
- -5.59
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.70
- Max
- 13.53
- Q3
- 6.54
- RGEN
- 4.70
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ELAN | RGEN |
|---|---|---|
| P/E Ratio (TTM) | -- | -- |
| P/S Ratio (TTM) | 2.50 | 13.77 |
| P/B Ratio (MRQ) | 1.95 | 4.70 |
| Free Cash Flow Yield (TTM) | -- | 1.01% |